An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Bendamustine (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 18 May 2017 Planned End Date changed from 1 Sep 2017 to 21 Jun 2017.
- 06 Dec 2016 Results (n=15) assessing PK parameters presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 02 Mar 2016 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.